MRI检测与分类淀粉样蛋白相关影像异常的真实世界挑战
抗淀粉样蛋白单克隆抗体治疗早期阿尔茨海默病需基线MRI排除禁忌及纵向监测ARIA-H和ARIA-E。本文综述高流量治疗项目中常见判读难点,如FLAIR信号异常、微出血计数不确定及ARIA-E与ARIA-H重叠,并提供管理导向建议。
要点
- 基线MRI需排除禁忌,随访重点识别ARIA-H和ARIA-E。
- FLAIR伪影、微出血计数不确定及ARIA-E/H重叠是常见灰色地带。
- 注意SWI和FLAIR技术因素、病灶检测变异及时间演变报告。
核心结论
- 识别ARIA判读陷阱可提高诊断信心,避免影响治疗决策的错误分类。
研究设计与样本
- 本文为影像聚焦综述,基于高流量抗淀粉样蛋白治疗项目的经验,总结真实世界判读挑战并提供实践建议。
关键影像表现/征象
- 基线筛查和ARIA监测中MRI表现有时不符合试验标准,呈临界或模糊类别。
- 细微或伪影性FLAIR信号异常、微出血计数不确定及ARIA-E与ARIA-H重叠特征可造成判读不确定性。
临床应用与阅片要点
- 关注影响SWI和FLAIR判读的技术因素,管理连续检查间病灶检测的变异。
- 准确报告ARIA相关表现的时间演变,以支持治疗管理决策。
局限性
- 原文未明确报告研究设计的局限;作为综述,缺乏系统检索和定量证据分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Anti-amyloid monoclonal antibody therapies (AATs) are increasingly used for the treatment of early symptomatic Alzheimer disease. Safe implementation of AATs relies on accurate assessment for exclusionary findings on baseline brain MRI and reliable longitudinal detection of amyloid-related imaging abnormalities (ARIA), including ARIA-H (hemosiderin or hemorrhage) and ARIA-E (edema or effusion). In routine clinical practice, MRI findings encountered during baseline screening and ARIA surveillance sometimes fall into borderline or ambiguous categories that do not clearly conform to trial-defined criteria. For example, subtle or artifactual FLAIR signal abnormality, equivocal microhemorrhage counts, and overlapping features of ARIA-E and ARIA-H can create uncertainty with direct implications for treatment management. Given limited practical guidance addressing these and other gray zones, this imaging-focused review synthesizes common interpretive challenges encountered in a high-volume AAT program and offers practical management-oriented recommendations. Key issues addressed include recognizing technical factors that affect interpretation of susceptibility-weighted and FLAIR images, managing variability in lesion detection across serial examinations, and accurately reporting the temporal evolution of ARIA-related findings. As AAT use expands, recognition of the presented pitfalls can improve diagnostic confidence and help avoid misclassification of findings that may influence therapeutic decisions.
引用
- Unger RH, Rohatgi S, Ferraciolli SF, et al. Real-World Challenges in the MRI Detection and Classification of Amyloid-Related Imaging Abnormalities. AJR Am J Roentgenol. 2026. PMID: 42684813. doi:10.2214/AJR.26.35478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。